<p>Junshi Biosciences (01877.HK) announced its preliminary results for the fiscal year 2025, reporting total revenue of RMB 2.498 billion (same below), an increase of 28.2% year-on-year. The net loss narrowed from RMB 1.281 billion in the previous year to RMB 874 million, with a loss per share of RMB 0.87</p>

512290

516820

159316

<p>Junshi Biosciences announced its preliminary performance report for the year 2025, achieving total operating revenue of 2.498 billion RMB (same below), an increase of 28.2% year-on-year. The net loss narrowed from 1.281 billion RMB in the previous year to 874 million RMB, with a loss per share of 0.87 RMB</p>

AASTOCKS

Guotai CSI Bio-medicine ETF

Ping An CSI Medicine and Medical Device Innovation ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Yinhua CSI Innovative Drugs Industry ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

JUNSHI BIO

China Merchants CSI Biotechnology Theme ETF

Junshi Biosciences

Founder Fubon CSI Medicine and Medical Device Innovation ETF

ChinaAMC CSI Biotechnology Theme ETF

Penghua SSE STAR Biology and Medicine ETF

Minsheng Royal CSI Biotechnology Theme ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Penghua CSI HK Connect Health Care Composite ETF

E Fund CSI Biotechnology Theme ETF

Tianhong CNI BIOMEDICINE ETF

ICBCCS SSE STAR Biology and Medicine ETF

Huaan Hang Seng Biotech ETF

"Performance" Junshi Biosciences' annual loss narrowed to 874 million RMB